EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Programmable Release of Chemotherapeutics from Ferrocene‐Based Injectable Hydrogels Slows Melanoma Growth

Rebecca Rothe, Yong Xu, Johanna Wodtke, Florian Brandt, Sebastian Meister, Markus Laube, Pier-Luigi Lollini, Yixin Zhang, Jens Pietzsch, Sandra Hauser iD

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202400265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Rebecca Rothe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, Bautz…. Hauptthemen laut MEDLINE: Hydrogels, Ferrous Compounds, Metallocenes, Doxorubicin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydrogel‐based injectable drug delivery systems provide temporally and spatially controlled drug release with reduced adverse effects on healthy tissues. Therefore, they represent a promising therapeutic option for unresectable solid tumor entities. In this study, a peptide‐starPEG/hyaluronic acid‐based physical hydrogel is modified with ferrocene to provide a programmable drug release orchestrated by matrix‐drug interaction and local reactive oxygen species (ROS). The injectable ROS‐responsive hydrogel (hiROSponse) exhibits adequate biocompatibility and biodegradability, which are important for clinical applications. HiROSponse is loaded with the two cytostatic drugs (hiROSponse dox/ptx ) doxorubicin (dox) and paclitaxel (ptx). Dox is a hydrophilic compound and its release is mainly controlled by Fickian diffusion, while the hydrophobic interactions between ptx and ferrocene can control its release and thus be regulated by the oxidation of ferrocene to the more hydrophilic state of ferrocenium. In a syngeneic malignant melanoma‐bearing mouse model, hiROSponse dox/ptx slows tumor growth without causing adverse side effects and doubles the relative survival probability. Programmable release is further demonstrated in a tumor model with a low physiological ROS level, where dox release, low dose local irradiation, and the resulting ROS‐triggered ptx release lead to tumor growth inhibition and increased survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrogelsFerrous CompoundsMetallocenesDoxorubicinPaclitaxelAnimalsMiceCell Line, TumorDrug LiberationAntineoplastic AgentsReactive Oxygen SpeciesMelanomaDrug Delivery SystemsFemaleHumansHyaluronic Acid

Stichwörter der Autor:innen

biodegradablelocal drug deliverynoncovalent hydrogelsequential drug releasesmall animal imaging

Substanzen

HydrogelsFerrous CompoundsferroceneMetallocenesDoxorubicinPaclitaxelAntineoplastic AgentsReactive Oxygen SpeciesHyaluronic Acid

Autor:innen und Institutionen

  • Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, Bautzner Landstrasse 400, 01328, Dresden, Germany.
  • Technische Universität Dresden, Faculty of Chemistry and Food Chemistry, School of Science, Bergstrasse 66, 01069, Dresden, Germany.
  • B CUBE Center for Molecular Bioengineering, Technische Universität Dresden, Tatzberg 41, 01307, Dresden, Germany.
  • Alma Mater Studiorum, University of Bologna, Department of Medical and Surgical Sciences, Viale Filopanti 22, Bologna, 40126, Italy.

ORCID-Profile: Sandra Hauser

Förderung

  • Deutsche Forschungsgemeinschaft
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China
  • Bundesministerium für Bildung und Forschung
  • Helmholtz Association
  • Gusu Innovation and Entrepreneur Leading Talents project

Zitieren

APA

Rothe, R., Xu, Y., Wodtke, J., Brandt, F., Meister, S., Laube, M., Lollini, P. L., Zhang, Y., Pietzsch, J., & Hauser, S. (2024). Programmable Release of Chemotherapeutics from Ferrocene‐Based Injectable Hydrogels Slows Melanoma Growth. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400265

Vancouver

Rothe R, Xu Y, Wodtke J, Brandt F, Meister S, Laube M, et al. Programmable Release of Chemotherapeutics from Ferrocene‐Based Injectable Hydrogels Slows Melanoma Growth. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400265

BibTeX
@article{Rothe2024,
  author = {Rothe, Rebecca and Xu, Yong and Wodtke, Johanna and Brandt, Florian and Meister, Sebastian and Laube, Markus and Lollini, Pier-Luigi and Zhang, Yixin and Pietzsch, Jens and Hauser, Sandra},
  title = {Programmable Release of Chemotherapeutics from Ferrocene‐Based Injectable Hydrogels Slows Melanoma Growth},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202400265}
}
Kostenlos starten →